CALY-002

Phase 1Biologic

CCalypso Biotech BV

CALY-002 is one of 43 biologic programs targeting Eosinophilic Esophagitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eosinophilic EsophagitisActive, not recruiting

Eosinophilic EsophagitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Eosinophilic Esophagitis

#DrugCompanyPhaseTrials

Pulmicort

SSalix

Approved

12 2

Prilosec

DDexcel Pharma Technologies Ltd.

Cinqair

2 4

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

10 5

Fasenra

AstraZeneca

Phase 3

1 6

Tezspire

AstraZeneca

Phase 3

1 7

Cromolyn Sodium

UUniversity of California, San Francisco

Approved

1 8

Xolair

Roche

Phase 2

2 9

Asmanex

Novartis

Phase 2

1 10

Lialda

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Eosinophilic Esophagitis1 trial

Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Completed·CCalypso Biotech BV·Phase 1·NCT04593251·73 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CALY-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CALY-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CALY-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Calypso Biotech BV company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCalypso Biotech BV

CALY-002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Eosinophilic Esophagitis1 trial

References

Drug Info

Quick Facts

Related News